Table 3.

A list of completed and ongoing clinical trials of combination treatment of Bev and Iri on GBM was obtained from www.clinicaltrials.gov (keywords: glioblastoma, bevacizumab, and irinotecan) until November 2022.

No.	Study name	Identifier	Condition or disease	Treatment	Study Phase	Description	Status	Starting date
1	A Study to Evaluate Bevacizumab Alone or in CombinationWith Irinotecan for Treatmentof Glioblastoma Multiforme (BRAIN) (BRAIN)	NCT00345163	Glioblastoma	- Bevacizumab- Irinotecan	Phase II	A Phase II, Multicenter, Randomized, Non- Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse	Completed	July 2006
2	A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas	NCT00921167	- Glioblastoma- Astrocytoma	- Bevacizumab- Irinotecan	Phase II	A Phase II Study to Evaluate the Efficacy of BevacizumabPlus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme	Completed	June2009

All data were collected from studies with only bevacizumab combined with irinotecan treatment. Data from withdraw, terminated, and suspended studies were excluded from the final summary.